Solventum Co. (NYSE:SOLV) Stake Boosted by Mitsubishi UFJ Asset Management Co. Ltd.

Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of Solventum Co. (NYSE:SOLV - Free Report) by 26.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 230,435 shares of the company's stock after buying an additional 47,547 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd. owned 0.13% of Solventum worth $15,467,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in Solventum by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 16,266,893 shares of the company's stock worth $1,074,591,000 after buying an additional 75,631 shares during the last quarter. State Street Corp boosted its holdings in Solventum by 3.1% in the third quarter. State Street Corp now owns 6,107,550 shares of the company's stock worth $425,818,000 after purchasing an additional 185,938 shares during the period. Geode Capital Management LLC raised its holdings in shares of Solventum by 4.0% during the third quarter. Geode Capital Management LLC now owns 3,347,719 shares of the company's stock worth $232,608,000 after purchasing an additional 128,317 shares during the period. Hotchkis & Wiley Capital Management LLC acquired a new position in shares of Solventum in the 3rd quarter valued at about $125,488,000. Finally, Boston Partners bought a new stake in shares of Solventum during the 4th quarter valued at about $110,378,000.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Bank of America lifted their target price on Solventum from $80.00 to $85.00 and gave the company a "neutral" rating in a research note on Wednesday, February 26th. Mizuho upped their price objective on Solventum from $70.00 to $82.00 and gave the stock a "neutral" rating in a research note on Monday, March 3rd. Piper Sandler raised their target price on Solventum from $75.00 to $84.00 and gave the company a "neutral" rating in a research note on Friday, February 28th. The Goldman Sachs Group upped their target price on shares of Solventum from $63.00 to $71.00 and gave the stock a "sell" rating in a research report on Monday, March 3rd. Finally, Morgan Stanley lifted their price target on Solventum from $73.00 to $80.00 and gave the company an "equal weight" rating in a report on Wednesday, March 5th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the company. According to MarketBeat, Solventum currently has an average rating of "Hold" and a consensus price target of $79.86.

Solventum Stock Down 5.7 %

NYSE:SOLV traded down $3.97 during trading hours on Friday, hitting $66.22. 1,873,221 shares of the stock traded hands, compared to its average volume of 1,359,517. The firm has a 50 day moving average price of $75.42 and a 200 day moving average price of $71.95. The firm has a market cap of $11.45 billion and a price-to-earnings ratio of 24.08. Solventum Co. has a fifty-two week low of $47.16 and a fifty-two week high of $85.92. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.